<table id="table5" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5	Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction
          
  
   <footnote id="t5f1">This table is not all inclusive.</footnote>
</caption>
<col align="left" valign="top" width="27%"></col>
<col align="left" valign="top" width="23%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule" valign="middle">Concomitant Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule" valign="middle">Effect on Concentration
            
    
     <footnote id="t5f2">↓ = decrease.</footnote>
</th>
<th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>carbamazepine
            
    
     <br/>phenytoin
            
    
     <br/>phenobarbital
            
    
     <br/>oxcarbazepine
           
   
    </td>
<td stylecode="Rrule">↓ sofosbuvir
            
    
     <br/>↓ GS-331007
           
   
    </td>
<td stylecode="Rrule">Coadministration of SOVALDI with carbamazepine, phenytoin, phenobarbital or oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>rifabutin
            
    
     <br/>rifampin
            
    
     <br/>rifapentine
           
   
    </td>
<td stylecode="Rrule">↓ sofosbuvir
            
    
     <br/>↓ GS-331007
           
   
    </td>
<td stylecode="Rrule">Coadministration of SOVALDI with rifabutin or rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.
            
    
     <br/>
<br/>SOVALDI should not be used with rifampin, a potent intestinal P-gp inducer 
            
    
     <content stylecode="italics">[See 
             
     
      <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].
            
    
     </content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Herbal Supplements:</content>
<br/>St. John's wort (
            
    
     <content stylecode="italics">Hypericum perforatum</content>)
           
   
    </td>
<td stylecode="Rrule">↓ sofosbuvir
            
    
     <br/>↓ GS-331007
           
   
    </td>
<td stylecode="Rrule">SOVALDI should not be used with St. John's wort, a potent intestinal P-gp inducer 
            
    
     <content stylecode="italics">[See 
             
     
      <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].
            
    
     </content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV Protease Inhibitors:</content>
<br/>tipranavir/ritonavir
           
   
    </td>
<td stylecode="Rrule">↓ sofosbuvir
            
    
     <br/>↓ GS-331007
           
   
    </td>
<td stylecode="Rrule">Coadministration of SOVALDI with tipranavir/ritonavir is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI.  Coadministration is not recommended.</td>
</tr>
</tbody>
</table>